PulmoXen: Phase I started

Xenetic said Pharmsynthez began an open-label, Russian Phase I trial to evaluate 2,500 and 5,000 units of PulmoXen in 12 healthy volunteers. Xenetic (formerly Lipoxen plc) has rights to develop and c...